[go: up one dir, main page]

MX2017016344A - Compuestos de benzoxacepina oxazolidinona y metodos de uso. - Google Patents

Compuestos de benzoxacepina oxazolidinona y metodos de uso.

Info

Publication number
MX2017016344A
MX2017016344A MX2017016344A MX2017016344A MX2017016344A MX 2017016344 A MX2017016344 A MX 2017016344A MX 2017016344 A MX2017016344 A MX 2017016344A MX 2017016344 A MX2017016344 A MX 2017016344A MX 2017016344 A MX2017016344 A MX 2017016344A
Authority
MX
Mexico
Prior art keywords
methods
pi3k
formula
oxazolidinone compounds
compounds
Prior art date
Application number
MX2017016344A
Other languages
English (en)
Other versions
MX372624B (es
Inventor
Hanan Emily
Macleod Calum
Andrew Heald Robert
Elliott Richard
T Staben Steven
Braun Marie-Gabrielle
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017016344A publication Critical patent/MX2017016344A/es
Publication of MX372624B publication Critical patent/MX372624B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se describen compuestos de benzoxacepina oxazolidinona con actividad o función moduladora de fosfoinosítido 3 cinasa (PI3K) que tienen la estructura de fórmula I: ( ver formula I ) o estereoisómeros, tautómeros, o sales farmacéuticamente aceptable de los mismos, y con los sustituyentes y características estructurales descritas en el presente documento. También se describen composiciones farmacéuticas y medicamentos que incluyen los compuestos de fórmula I, así como métodos para usar dichos moduladores de PI3K, solos o en combinación con otros agentes terapéuticos, para tratar enfermedades o afecciones que están mediadas o que son dependientes de la desregulación de PI3K.
MX2017016344A 2015-07-02 2016-07-01 Compuestos de benzoxacepina oxazolidinona y metodos de uso MX372624B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562188029P 2015-07-02 2015-07-02
PCT/EP2016/065455 WO2017001645A1 (en) 2015-07-02 2016-07-01 Benzoxazepin oxazolidinone compounds and methods of use

Publications (2)

Publication Number Publication Date
MX2017016344A true MX2017016344A (es) 2018-05-02
MX372624B MX372624B (es) 2025-03-05

Family

ID=56292756

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003415A MX2020003415A (es) 2015-07-02 2016-07-01 Compuestos de benzoxacepina oxazolidinona y métodos de uso.
MX2017016344A MX372624B (es) 2015-07-02 2016-07-01 Compuestos de benzoxacepina oxazolidinona y metodos de uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020003415A MX2020003415A (es) 2015-07-02 2016-07-01 Compuestos de benzoxacepina oxazolidinona y métodos de uso.

Country Status (33)

Country Link
US (6) US9650393B2 (es)
EP (4) EP3317284B1 (es)
JP (4) JP6523490B2 (es)
KR (2) KR102014326B1 (es)
CN (4) CN112062778B (es)
AR (1) AR105238A1 (es)
AU (2) AU2016287463B2 (es)
CA (1) CA2982708C (es)
CL (1) CL2017003436A1 (es)
CO (1) CO2017011038A2 (es)
CR (1) CR20170563A (es)
DK (1) DK3317284T3 (es)
ES (2) ES2764497T3 (es)
HK (1) HK1253003A1 (es)
HR (1) HRP20192349T1 (es)
HU (1) HUE046756T2 (es)
IL (3) IL255200B (es)
LT (1) LT3317284T (es)
MA (3) MA42295B1 (es)
MX (2) MX2020003415A (es)
MY (1) MY195002A (es)
PE (2) PE20181021A1 (es)
PH (2) PH12017502425A1 (es)
PL (2) PL3317284T3 (es)
PT (1) PT3317284T (es)
RS (1) RS59740B1 (es)
RU (1) RU2730529C2 (es)
SG (1) SG10201913980SA (es)
SI (1) SI3317284T1 (es)
TW (4) TWI698440B (es)
UA (1) UA121678C2 (es)
WO (1) WO2017001645A1 (es)
ZA (1) ZA201808370B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107995911B (zh) 2015-07-02 2020-08-04 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
CN112979660A (zh) 2015-07-02 2021-06-18 豪夫迈·罗氏有限公司 二环内酰胺和其应用方法
CN112062778B (zh) * 2015-07-02 2024-04-19 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
CN108349996B (zh) 2015-09-08 2021-01-08 豪夫迈·罗氏有限公司 三环pi3k抑制剂化合物及其使用方法
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
ES2953833T3 (es) * 2016-12-15 2023-11-16 Hoffmann La Roche La invención se refiere a procedimientos de preparación de compuestos de benzoxacepina oxazolidinona e intermedios útiles
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
US20180339997A1 (en) * 2017-04-28 2018-11-29 Genentech, Inc. Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
CN112074519B (zh) 2018-04-20 2024-08-02 豪夫迈·罗氏有限公司 作为rip1激酶抑制剂用于治疗例如肠易激综合征(ibs)的化合物
CN110785423B (zh) * 2018-05-30 2022-07-26 江苏豪森药业集团有限公司 含三并环类衍生物抑制剂、其制备方法和应用
WO2020023297A1 (en) * 2018-07-23 2020-01-30 Genentech, Inc. Methods of treating cancer with pi3k inhibitor, gdc-0077
TW202027736A (zh) 2018-10-08 2020-08-01 瑞士商赫孚孟拉羅股份公司 用PI3Kα抑制劑及二甲雙胍治療癌症之方法
CN109265408B (zh) * 2018-12-11 2020-09-01 上海皓元生物医药科技有限公司 二氟甲基取代噁烷-2-酮的合成方法
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
CN111995541A (zh) * 2019-05-27 2020-11-27 润佳（苏州）医药科技有限公司 含有稳定重同位素的酰胺官能团的化合物及其应用
US12208095B2 (en) 2019-08-26 2025-01-28 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN114599656A (zh) * 2019-11-04 2022-06-07 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
CN113227101B (zh) * 2019-11-25 2024-10-11 上海翰森生物医药科技有限公司 含三并环类衍生物的盐或晶型及其药物组合物
CN112830935B (zh) * 2019-11-25 2023-12-22 上海翰森生物医药科技有限公司 含三并环类衍生物自由碱的晶型及其药物组合物
AU2020396093A1 (en) * 2019-12-03 2022-05-19 Genentech, Inc. Combination therapies for treatment of breast cancer
IL303502A (en) 2020-12-11 2023-08-01 Genentech Inc Combination therapies for treatment of her2 cancer
US20240390388A1 (en) * 2021-01-29 2024-11-28 Medshine Discovery Inc. Tricyclic compounds and use thereof
CA3218470A1 (en) 2021-05-13 2022-11-17 Betta Pharmaceuticals Co., Ltd. Polymorph of imidazolidinone compound, preparation method therefor and use thereof
AU2022282440A1 (en) 2021-05-28 2023-11-16 Genentech, Inc. Process for the preparation of benzoxazepin oxazolidinone compounds
JP7537026B2 (ja) 2021-07-19 2024-08-20 京セラ株式会社 通信方法、ユーザ装置、ネットワーク装置、移動通信システム、プログラム及びチップセット
AU2022325819A1 (en) * 2021-08-09 2024-02-29 Scorpion Therapeutics, Inc. Compounds that inhibit pi3k isoform alpha and methods for treating cancer
EP4504202A1 (en) 2022-04-06 2025-02-12 Genentech Inc. Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
CN117466913A (zh) * 2022-07-27 2024-01-30 南京明德新药研发有限公司 一种5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英化合物的晶型及其制备方法
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
TW202440096A (zh) 2023-03-24 2024-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案
WO2025036856A1 (en) 2023-08-11 2025-02-20 F. Hoffmann-La Roche Ag Pharmaceutical formulation comprising a coated tablet

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
PT3029041T (pt) 2000-04-25 2020-05-13 Icos Corp Inibidores de fosfatidil-inositol 3-quinase delta humana
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
PT1696931E (pt) 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
ME02688B (me) 2004-05-13 2017-10-20 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EA200702235A1 (ru) 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
MY162174A (en) 2005-10-07 2017-05-31 Exelixis Inc Azetidines mek inhibitors for the treatment of proliferative diseases
WO2007129161A2 (en) 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
GB0610866D0 (en) 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
HUE025459T2 (hu) 2006-09-22 2016-05-30 Pharmacyclics Inc A Bruton-féle tirozin-kináz inhibitorai
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CL2007003520A1 (es) * 2006-12-07 2008-08-22 Piramed Ltd Genentech Inc Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
JP5529746B2 (ja) * 2007-11-21 2014-06-25 デコード ジェネティクス イーエイチエフ 炎症性疾患、心臓血管疾患及び中枢神経系障害を治療するための置換されたベンゾアゾールｐｄｅ４阻害剤
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
AU2010299820A1 (en) * 2009-09-28 2012-04-19 F. Hoffmann-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
RU2600927C2 (ru) * 2009-09-28 2016-10-27 Ф.Хоффманн-Ля Рош Аг Бензоксазепиновые ингибиторы pi3k и способы применения
WO2011056930A2 (en) * 2009-11-06 2011-05-12 Emory University Fragile x mental retardation protein (fmrp), compositions, and methods related thereto
CN103562210B (zh) * 2011-03-21 2016-05-25 弗·哈夫曼-拉罗切有限公司 对pI3K 110δ具有选择性的苯并氧氮杂*化合物及使用方法
JP5832647B2 (ja) 2011-07-01 2015-12-16 ノバルティス アーゲー がんの治療における使用のためのｃｄｋ４／６阻害剤およびｐｉ３ｋ阻害剤を含む併用療法
NO3175985T3 (es) 2011-07-01 2018-04-28
UY34632A (es) * 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
BR112014021935A2 (pt) 2012-03-05 2019-09-24 Gilead Calistoga Llc formas polimórficas de (s)-2(l-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolina-4(3h)ona
CN104245218B (zh) * 2012-03-30 2017-07-04 布莱阿姆青年大学 用于摩擦搅拌操作的过程控制的作用力调制
KR101689946B1 (ko) 2012-06-08 2016-12-26 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
KR20180070715A (ko) * 2013-03-13 2018-06-26 에프. 호프만-라 로슈 아게 벤즈옥사제핀 화합물의 제조 방법
JP6260967B2 (ja) * 2013-11-06 2018-01-17 国立大学法人京都大学 放射性ヨウ素標識化合物、及び、これを含む放射性医薬
CN107995911B (zh) 2015-07-02 2020-08-04 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
CN112062778B (zh) 2015-07-02 2024-04-19 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
ES2953833T3 (es) 2016-12-15 2023-11-16 Hoffmann La Roche La invención se refiere a procedimientos de preparación de compuestos de benzoxacepina oxazolidinona e intermedios útiles
US20180339997A1 (en) * 2017-04-28 2018-11-29 Genentech, Inc. Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
WO2020023297A1 (en) 2018-07-23 2020-01-30 Genentech, Inc. Methods of treating cancer with pi3k inhibitor, gdc-0077
TW202027736A (zh) 2018-10-08 2020-08-01 瑞士商赫孚孟拉羅股份公司 用PI3Kα抑制劑及二甲雙胍治療癌症之方法
AU2020396093A1 (en) 2019-12-03 2022-05-19 Genentech, Inc. Combination therapies for treatment of breast cancer

Also Published As

Publication number Publication date
KR20180006460A (ko) 2018-01-17
UA121678C2 (uk) 2020-07-10
IL255200B (en) 2020-05-31
ES2764497T3 (es) 2020-06-03
US20210246129A1 (en) 2021-08-12
IL272277A (en) 2020-02-27
CN112062778B (zh) 2024-04-19
TWI698440B (zh) 2020-07-11
IL255200A0 (en) 2017-12-31
ES2908300T3 (es) 2022-04-28
JP2019178135A (ja) 2019-10-17
TWI601732B (zh) 2017-10-11
CN112047960B (zh) 2024-08-02
DK3317284T3 (da) 2020-01-13
EP4212536C0 (en) 2025-02-19
PE20211775A1 (es) 2021-09-08
MX2020003415A (es) 2021-12-07
JP2021119144A (ja) 2021-08-12
CR20170563A (es) 2018-02-20
JP2018519307A (ja) 2018-07-19
SG10201913980SA (en) 2020-03-30
EP3778607A1 (en) 2021-02-17
CN111909173A (zh) 2020-11-10
NZ736222A (en) 2024-05-31
KR20190100432A (ko) 2019-08-28
US20240199594A1 (en) 2024-06-20
AU2016287463B2 (en) 2020-07-02
LT3317284T (lt) 2020-01-27
WO2017001645A1 (en) 2017-01-05
HRP20192349T1 (hr) 2020-03-20
PT3317284T (pt) 2020-01-10
TW202108592A (zh) 2021-03-01
EP3567045B1 (en) 2022-01-12
SI3317284T1 (sl) 2020-02-28
EP3567045A1 (en) 2019-11-13
CA2982708C (en) 2023-10-03
CL2017003436A1 (es) 2018-05-04
MA42295B1 (fr) 2020-02-28
CN107873032A (zh) 2018-04-03
US10112932B2 (en) 2018-10-30
PE20181021A1 (es) 2018-06-27
JP6880101B2 (ja) 2021-06-02
CO2017011038A2 (es) 2018-02-09
KR102014326B1 (ko) 2019-08-26
AR105238A1 (es) 2017-09-20
BR112017023121A2 (pt) 2018-07-10
US9650393B2 (en) 2017-05-16
CN107873032B (zh) 2020-07-17
CN112062778A (zh) 2020-12-11
RU2018103454A (ru) 2019-08-05
US20190263793A1 (en) 2019-08-29
ZA201808370B (en) 2023-03-29
PL3317284T3 (pl) 2020-04-30
HUE046756T2 (hu) 2020-03-30
EP3778607B1 (en) 2023-08-30
PL3567045T3 (pl) 2022-04-19
MA49861A (fr) 2021-05-05
IL272277B (en) 2021-01-31
RU2730529C2 (ru) 2020-08-24
RS59740B1 (sr) 2020-02-28
PH12017502425A1 (en) 2018-07-02
AU2020204418B2 (en) 2022-02-03
CN111909173B (zh) 2025-03-04
US20180127404A1 (en) 2018-05-10
PH12020551315A1 (en) 2021-07-05
KR102306071B1 (ko) 2021-10-01
US11760753B2 (en) 2023-09-19
TW201712020A (zh) 2017-04-01
EP4212536B1 (en) 2025-02-19
CN112047960A (zh) 2020-12-08
HK1253003A1 (zh) 2019-06-06
MY195002A (en) 2022-12-30
IL277774A (en) 2020-11-30
EP4212536A1 (en) 2023-07-19
US10851091B2 (en) 2020-12-01
US20170210733A1 (en) 2017-07-27
MA54252A (fr) 2022-04-27
EP3778607C0 (en) 2023-08-30
NZ775526A (en) 2024-05-31
JP2023103242A (ja) 2023-07-26
AU2020204418A1 (en) 2020-07-23
US20170015678A1 (en) 2017-01-19
JP6523490B2 (ja) 2019-06-05
CA2982708A1 (en) 2017-01-05
JP7266630B2 (ja) 2023-04-28
TW201815798A (zh) 2018-05-01
TW201936612A (zh) 2019-09-16
EP3317284A1 (en) 2018-05-09
EP3317284B1 (en) 2019-10-30
RU2018103454A3 (es) 2019-11-21
TWI649326B (zh) 2019-02-01
AU2016287463A1 (en) 2017-10-26
MX372624B (es) 2025-03-05

Similar Documents

Publication Publication Date Title
MX2017016344A (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso.
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
MX2017007489A (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos.
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
UY35633A (es) Inhibidores de bromodominios
MX375484B (es) Derivados de azabencimidazol como inhibidores de pi3k beta
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
NI201500140A (es) Compuestos y composiciones terapéuticos
CO2019009722A2 (es) Dendrímeros terapéuticos
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
MX2017001603A (es) Derivados de piperazina como moduladores de los receptores x del higado.
PE20151607A1 (es) Formulaciones de compuestos organicos
UY36608A (es) Derivados de indol

Legal Events

Date Code Title Description
FG Grant or registration